Details of Disease

General Information of Disease (ID: DISJEIJ5)

• Disease Name: Yersinia infection
• Synonyms: Yersinia infection; infections, Yersinia <bacteria>; infections, Yersinia; infection, Yersinia; Yersinia <bacteria> infection; yersiniosis
• Disease Class: 1B93: Plague
• Definition: Infections with bacteria of the genus yersinia.
• Disease Hierarchy:
  DIS5QJ9S: Bacterial infection
  DISEM33Q: Infectious disease
  DISJEIJ5: Yersinia infection
• ICD Code:
  ICD-11: ICD-11: 1B93
  ICD-9: ICD-9: 20
  Expand ICD-9: 20

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 4 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Botulinum toxin vaccine	DMXYFVY	Phase 2	NA	[1]
Plague vaccine	DMT3PJP	Phase 2	NA	[2]
Recombinant botulinum toxin vaccine	DM382VP	Phase 2	NA	[3]
Recombinant plague F1V vaccine	DM2VQZH	Phase 2	NA	[4]

This Disease is Treated as An Indication in 3 Discontinued Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
BT-VACC	DMNRIAJ	Discontinued in Phase 2	NA	[5]
RypVax	DMI26UF	Discontinued in Phase 2	NA	[6]
Yersinia pestis vaccine	DMR2O4N	Terminated	NA	[7]

This Disease is Treated as An Indication in 1 Investigative Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
MSL-143438	DM1K7CU	Investigative	NA	[8]

Molecular Interaction Atlas (MIA) of This Disease

References

• [1] The receptor binding domain of botulinum neurotoxin serotype A (BoNT/A) inhibits BoNT/A and BoNT/E intoxications in vivo. Clin Vaccine Immunol. 2013 Aug;20(8):1266-73.
• [2] ClinicalTrials.gov (NCT01122784) Randomized Single-Blinded Study to Evaluate Safety and Immunogenicity of Recombinant Plague Vaccine With and Without Adjuvant. U.S. National Institutes of Health.
• [3] CSC's dynport vaccine company releases results for Phase 2 botulinum vaccine clinical trial. CSC. January 24, 2012.
• [4] ClinicalTrials.gov (NCT00332956) Title: Recombinant Plague Vaccine rF1V in Healthy Volunteers. U.S. National Institutes of Health.
• [5] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800018825)
• [6] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800024730)
• [7] Clinical pipeline report, company report or official report of Mucosis BV.
• [8] The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.